Pharmathen Eyes US Growth As Owner Announces Sale
BC Partners Divests Pharmathen To Swiss-Based Partners Group
With plans to drive continuous innovation in drug administration technology and further implement state-of-the-art production capabilities, Swiss-based private equity Partners Group has announced a deal to acquire long-acting injectables specialist Pharmathen.
You may also be interested in...
Three years after rebranding from Concordia, Advanz Pharma is to be swallowed up by European-focused private equity Nordic Capital.
Private-equity firm BC Partners has struck a deal to acquire a majority stake in Synthon International Holding.
Teva CEO Kåre Schultz has spoken at great length and in great detail about Teva’s ability to reach a proposed settlement in the US over allegations the firm helped fuel the opioid epidemic, revealing that a deal may be only 12 months away.